Viewing Study NCT02684058


Ignite Creation Date: 2025-12-25 @ 12:20 AM
Ignite Modification Date: 2026-02-12 @ 4:45 PM
Study NCT ID: NCT02684058
Status: COMPLETED
Last Update Posted: 2023-12-13
First Post: 2016-02-04
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Sponsor: Novartis Pharmaceuticals
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Diffuse Astrocytoma View
None Anaplastic Astrocytoma View
None Astrocytoma View
None Oligodendroglioma, Childhood View
None Anaplastic Oligodendroglioma View
None Glioblastoma View
None Pilocytic Astrocytoma View
None Giant Cell Astrocytoma View
None Pleomorphic Xanthoastrocytoma View
None Anaplastic Pleomorphic Xanthoastrocytoma View
None Angiocentric Glioma View
None Chordoid Glioma of Third Ventricle View
None Gangliocytoma View
None Ganglioglioma View
None Anaplastic Ganglioglioma View
None Dysplastic Gangliocytoma of Cerebrellum View
None Desmoplastic Infantile Astrocytoma and Ganglioglioma View
None Papillary Glioneuronal Tumor View
None Rosette-forming Glioneurona Tumor View
None Central Neurocytoma View
None Extraventricular Neurocytoma View
None Cerebellar Iponeurocytoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Malignant glioma View
None BRAF mutant positive View
None High grade glioma View
None Low grade glioma View
None Dabrafenib View
None Trametinib View
None Pediatrics View
None Brain neoplasma View